Home > Keywords > Thématique > Science

Science

Articles

  • How blood–brain barrier technology is unleashing CNS therapies
    18 March 2025, by Emmanuelle BETTENDORF

    We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
    This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
    Click below for the full article.
    👉 (…)

  • Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
    22 March 2022, by Elodie DORMES

    Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.

  • Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
    3 April 2023, by Elodie DORMES

    Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
    Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our (…)

  • Vect-Horus will be attending the #EANM 2022 Annual Congress
    18 October 2022, by Elodie DORMES

    Great occasion to assist to valuable conferences about Nuclear Medicine, Molecular Imaging, Optimization of Radiolabeled Biomolecules in one of the most valuable Nuclear Medicine event in Europe.
    Meet with Cedric MALICET, PhD during the EANM on Oct 15-19, 2022 in Barcelona.

  • Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.
    16 November 2022, by Elodie DORMES

    Guillaume JACQUOT will share a presentation on “Targeted delivery of Therapeutic Oligonucleotides to CNS by systemic administration” a good opportunity for Vect-Horus to present its last results.
    Emmanuelle BETTENDORF will be there as well to assist to conferences about Emerging #Oligonuleotide Therapeutics, #Delivery Strategies for Oligonucleotides, Peptides and mRNA and meet with all actors in the field.

  • Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
    15 May 2024, by Emmanuelle BETTENDORF

    The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
    The study showed that these vectors have the potential to improve delivery of medication to the (…)

  • Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by Vect-Horus
    28 January 2019, by Jonathan NOWAK

    Two groups of the Institute of Hematology, Huazhong University in Wuhan and the Key Laboratory of Smart Drug Delivery, Fudan University in Shanghai, well known and specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma, show evidence in mice (Zhang et al., 2013, Biomaterials) of nanoparticle targeting to the brain and glioblastoma with therapeutic benefit, with one of the peptide vectors described by VECT-HORUS in Malcor et al. (2012, J Med Chem).

  • Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
    28 January 2019, by Jonathan NOWAK

    (Molino et al., 2017, The FASEB Journal)
    www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

  • Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
    8 September 2023, by Emmanuelle BETTENDORF

    On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)” will be given Sunday, September 10th between 4:55 PM and 5:05 PM at the Hall E2 by Izabela Tworowska.
    Come and take the opportunity to meet and discuss with Vect-Horus on September 9-13, 2023 in Vienna!
    Our #Oncology team, Cedric (…)

  • ECMED EU-GliaPhD international conference in MALTA
    28 January 2019, by Jonathan NOWAK

    Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel Khrestchatisky will give a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.